Hari, Parameswaran
Matous, Jeffrey V.
Voorhees, Peter M.
Shain, Kenneth H.
Obreja, Mihaela
Frye, John
Fujii, Hisaki
Jakubowiak, Andrzej J.
Rossi, Davide
Sonneveld, Pieter
Funding for this research was provided by:
Amgen Foundation
Article History
Received: 12 June 2019
Accepted: 29 July 2019
First Online: 16 August 2019
Conflict of interest
: P.H. reports consultancy, honoraria, and researching funding from Celgene. J.V.M. reports speakers bureau from Celgene and membership on an entity’s board of directors or advisory committees from Multiple Myeloma Advisory Committee. P.M.V. reports consultancy from Novartis, Oncopeptides, Takeda, and TeneoBio; advisory board partipation for Bristol-Myers Squibb, Celgene, and Janssen; and speakers bureau participation for Amgen and Janssen. K.H.S. reports speakers bureau and advisory board participation for Amgen, Celgene, Takeda, Janssen, and Bristol-Myers Squibb; research grant funding from AbbVie; and steering committee participation for AbbVie and Celgene. M.O., J.F., and H.F. report employment and stock holdings from Amgen. A.J.J. reports consultancy, honoraria, and membership on an entity’s Board of Directors or Advisory Committees fees from Amgen, AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Karyopharm, Millennium, Takeda, Sanofi, and SkylineDx. D.R. and P.S. have no conflict of interest.